ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

ClinicalTrials.gov ID: NCT07023614

Public ClinicalTrials.gov record NCT07023614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - FORTITUDE-HCM

Study identification

NCT ID
NCT07023614
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Enrollment
165 participants

Conditions and interventions

Interventions

  • Ninerafaxstat 200mg MR Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 5, 2025
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026
Last update posted
May 17, 2026

2025 – 2026

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
Imbria Investigational Site La Jolla California 92037 Recruiting
Imbria Investigational Site Los Angeles California 90048 Recruiting
Imbria Investigational Site San Francisco California 94143 Recruiting
Imbria Investigational Site Washington D.C. District of Columbia 20010 Recruiting
Imbria Investigational Site Miami Florida 33136 Recruiting
Imbria Investigational Site Chicago Illinois 60611 Recruiting
Imbria Investigational Site Oak Lawn Illinois 60453 Not yet recruiting
Imbria Investigational Site Baltimore Maryland 21218 Recruiting
Imbria Investigational Site Boston Massachusetts 02114 Recruiting
Imbria Investigational Site Burlington Massachusetts 01805 Recruiting
Imbria Investigational Site Grand Rapids Michigan 49503 Recruiting
Imbria Investigational Site Rochester Minnesota 55905 Recruiting
Imbria Investigational Site St Louis Missouri 63110 Recruiting
Imbria Investigational Site New York New York 10016 Recruiting
Imbria Investigational Site Charlotte North Carolina 28204 Recruiting
Imbria Investigational Site Portland Oregon 97239 Recruiting
Imbria Investigational Site Philadelphia Pennsylvania 19104 Recruiting
Imbria Investigational Site Philadelphia Pennsylvania 19107 Recruiting
Imbria Investigational Site Houston Texas 77030 Recruiting
Imbria Investigational Site Plano Texas 75093 Recruiting
Imbria Investigational Site Charlottesville Virginia 22903 Recruiting
Imbria Investigational Site Richmond Virginia 23298 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07023614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 17, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07023614 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →